Literature DB >> 25537020

Multifocality in neurofibromatosis type 2.

D Gareth R Evans1, Stavros M Stivaros1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25537020      PMCID: PMC4483081          DOI: 10.1093/neuonc/nou338

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

Review 1.  Management of the patient and family with neurofibromatosis 2: a consensus conference statement.

Authors:  D G R Evans; M E Baser; B O'Reilly; J Rowe; M Gleeson; S Saeed; A King; S M Huson; R Kerr; N Thomas; R Irving; R MacFarlane; R Ferner; R McLeod; D Moffat; R Ramsden
Journal:  Br J Neurosurg       Date:  2005-02       Impact factor: 1.596

2.  Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.

Authors:  Ramita Dewan; Alex Pemov; H Jeffrey Kim; Keaton L Morgan; Raul A Vasquez; Prashant Chittiboina; Xiang Wang; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; John A Butman; Douglas R Stewart; Ashok R Asthagiri
Journal:  Neuro Oncol       Date:  2014-12-01       Impact factor: 12.300

3.  Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2.

Authors:  M Samii; C Matthies; M Tatagiba
Journal:  Neurosurgery       Date:  1997-04       Impact factor: 4.654

4.  Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.

Authors:  A Mohyuddin; W J Neary; A Wallace; C L Wu; S Purcell; H Reid; R T Ramsden; A Read; G Black; D G R Evans
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

5.  Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.

Authors:  J G Rowe; M W R Radatz; L Walton; T Soanes; J Rodgers; A A Kemeny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

6.  Type 2 neurofibromatosis: the need for supraregional care?

Authors:  D G Evans; R Ramsden; S M Huson; R Harris; R Lye; T T King
Journal:  J Laryngol Otol       Date:  1993-05       Impact factor: 1.469

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases.

Authors:  R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

9.  Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment.

Authors:  R L Martuza; R G Ojemann
Journal:  Neurosurgery       Date:  1982-01       Impact factor: 4.654

10.  Hearing preservation in neurofibromatosis type 2.

Authors:  W H Slattery; D E Brackmann; W Hitselberger
Journal:  Am J Otol       Date:  1998-09
View more
  1 in total

1.  Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.

Authors:  Ka-Loh Li; Ibrahim Djoukhadar; Xiaoping Zhu; Sha Zhao; Simon Lloyd; Martin McCabe; Catherine McBain; D Gareth Evans; Alan Jackson
Journal:  Neuro Oncol       Date:  2015-08-26       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.